Hong Kong Red Cross

Cerus Corporation Announces a Five-Year Tender Award by the Hong Kong Red Cross Blood Transfusion Service for INTERCEPT Blood Systems

Retrieved on: 
Thursday, July 30, 2020
Biotechnology, Hospitals, Health, Cardiology, Medical Supplies, Blood, Transfusion medicine, Branches of biology, Body fluids, BTS, Blood transfusion, Hong Kong Red Cross, Platelet, NHS Blood and Transplant, Hong Kong

Cerus Corporation (Nasdaq:CERS) today announced it has been awarded a five-year tender by the Hong Kong Red Cross Blood Transfusion Services (BTS) for INTERCEPT Blood System for platelets.

Key Points: 
  • Cerus Corporation (Nasdaq:CERS) today announced it has been awarded a five-year tender by the Hong Kong Red Cross Blood Transfusion Services (BTS) for INTERCEPT Blood System for platelets.
  • The Hong Kong Red Cross BTS is the only public institution providing blood to all hospitals, public and private, in Hong Kong.
  • The Hong Kong Red Cross BTS is a member of the influential Asia Pacific Blood Network (APBN) and a key opinion leader globally.
  • The tender award builds upon the prior experience of the Hong Kong Red Cross BTS with the INTERCEPT Blood System for platelets.